Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

Jean Hoffman-Censits, MD
Published: Wednesday, Oct 04, 2017



Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.

The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.
 
SELECTED
LANGUAGE


Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.

The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x